Health technology assessment (HTA) body NICE has issued preliminary guidance recommending against making two new drugs for rare diseases available on England’s National Health Service – Orladeyo (berotralstat), from BioCryst Pharmaceuticals, for preventing hereditary angioedema, and Celgene’s myelofibrosis treatment, Inrebic (fedratinib).
Neither oral drug would be a cost-effective use of NHS resources, according to NICE, which also has concerns over the...








